[Adobe Stock]
The conference will kick off on May 4 with an Opening Plenary (3:00–4:30 PM ET), where experts will offer perspective on the current challenges and breakthroughs within the biotechnology field.
Throughout the NBC, a variety of pre-recorded Prologue Sessions will offer deeper dives into specific topics such as AI-driven dosage form selection, intravitreal drug delivery innovations, and the complexities of characterizing and analyzing advanced biologics. Leading the sessions are experts who will offer practical insights and real-world advice.
For example, AI Solutions for Dose and Dosage Form Selection in Drug Clinical Development, presented by Sruthi Sarvepalli, MS (St. John’s University), will explore how artificial intelligence can streamline dosing accuracy and improve clinical outcomes, while Intravitreal Drug Delivery: Overcoming Formulation and Device Challenges, led by Prof. Dr. Andrea Allmendinger (ten23 health AG), will highlight the latest strategies for administering medications directly into the eye.
On May 5, the Executive Track (8:00–9:30 AM ET) will examine critical decision-making processes in the session Developability and Due Diligence: How to Assess, Draw, and Sometimes End the Road(map) for New and Unusual Modalities, moderated by Jef Akst, MS (BioSpace). This session will address the strategic factors that influence whether emerging drug candidates advance to the next stage of development, and under what circumstances projects should be halted.
The conference will also feature several Key Symposia, which will provide in-depth explorations of pressing topics in biotechnology. Two standout symposia are:
- Accelerating Novel Formulation Development of Biologics for Newer and Established Modalities (May 5, 9:30–11:00 AM ET) – Moderated by Rikhav Gala, this session will focus on ways to overcome formulation challenges, reduce development timelines, and bring innovative therapies to patients more efficiently.
- Bioprocessing, Characterization & Comparability for Complex Biologics (May 6, 9:30–11:00 AM ET) – Moderated by Sheetal S. Pai-Wechsung, PhD (Pfizer Inc), attendees will learn best practices for managing manufacturing processes and ensuring product consistency, especially for complex or advanced biologics.
Two Keynote Addresses will highlight how biotechnology is pushing the boundaries of what is possible:
- Challenges in Characterization and Comparability of Advanced Therapies (May 5, 1:00–2:00 PM ET) – Phillip Ramsey, MS, MBA (Sangamo Therapeutics) will offer his perspective on maintaining consistent quality and therapeutic efficacy for emerging platforms such as cell and gene therapies.
- Harnessing Bioinspiration for the Delivery of Protein and Nucleic Acid-Based Biotherapeutics (May 6, 1:00–2:00 PM ET) – Stephen T. Buckley, PhD (Novo Nordisk A/S) will discuss nature-inspired, cutting-edge delivery strategies for protein and RNA-based treatments, exploring how to optimize and scale up these innovative approaches.
The Closing Plenary (May 7, 3:00–4:00 PM ET) will bring together the most impactful insights from the entire conference, offering a forward-looking perspective on the future of biotechnology. This session will include summaries of key findings, discussions of next steps for clinical translation, and strategies for continued innovation.
Filed Under: Biologics
